Please complete this form relating to your transactions in Laboratory Corporation of America Holdings (NYSE: LH) between July 29, 2021 and December 31, 2021.
You may also contact James Maro, Esq. (484) 270-1453; or you may submit your information via email at firstname.lastname@example.org; or you may click here to print a PDF of this form.
Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Laboratory Corporation of America Holdings (NYSE: LH) (“Labcorp”) securities between July 29, 2021 and December 31, 2021.
Labcorp investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.
Labcorp is an independent clinical laboratory company that offers various tests, including blood chemistry analyses, urinalyses, and blood cell counts. Specifically, Labcorp’s products include a prenatal blood test that purportedly detects developmental problems in the DNA of a fetus with remarkable accuracy.
On January 1, 2022, The New York Times published an article questioning the accuracy of Labcorp’s prenatal blood tests. Specifically, the article indicated, among other things, that the positive results of the prenatal blood tests offered by Labcorp are “incorrect about 85 percent of the time.” Additionally, the article revealed that “patients who receive a positive result are supposed to pursue follow-up testing,” but that such tests “can cost thousands of dollars, come with a small risk of miscarriage and can’t be performed until later in pregnancy.”
Following this news, Labcorp’s stock fell $16.03, or 5%, to close at $298.18 per share on January 3, 2022.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or via e-mail at email@example.com.